The Department of Health and Human Services, through the Food and Drug Administration (FDA), is seeking small businesses to develop Amb a 1-specific capture and biotin-labeled detection aptamers for use in Enzyme Linked Immunosorbent Assay (ELISA) applications. The objective of this procurement is to create reference standard aptamers that will facilitate the measurement of biological potencies in commercial ragweed pollen extracts, which are crucial for allergen standardization in the United States. This initiative underscores the importance of advancing biotechnology in allergen detection, particularly in relation to ragweed, a common allergen. Interested parties should submit their quotes in response to Request for Quotations (RFQ) No. 75F40124Q00548, with the contract anticipated to last from September 30, 2024, to September 29, 2025. For further inquiries, potential offerors can contact Nicholas Bisher at Nicholas.Bisher@fda.hhs.gov.